Skip to main content
. 2021 Apr 23;16(4):e0248380. doi: 10.1371/journal.pone.0248380

Fig 8. Xenograft tumor growth under vehicle, rapamycin, INK 128, ganetespib (a, b) combined ganetespib and INK 128 (c) and ganetespib and rapamycin (d) treatment.

Fig 8

Tumor volume is shown as normalized to tumor volume at day 1 of treatment. Tumor size is shown as mean and standard deviation. Normalized tumor size of different treatment groups was compared on day 22 using Wilcoxon Rank Sum test. P-values less than 0.05 were considered statistically significant. Mice were treated with rapamycin (3 mg/kg, 3x/week, i.p., n = 5), INK 128(1mg/kg, 5x/week, i.g., n = 5) or ganetespib (50mg/kg, 1x/week, i.v., n = 9) (a) or in combination of ganetespib and INK 128 (n = 5) (c) or ganetespib and rapamycin (n = 6) (d). Tumor size of treated mice is significantly smaller on day 22 compared to mice, which received vehicle (n = 8) (b).